Acute promyelocytic leukemia: What is the new standard of care? Journal Article
| Authors: | Watts, J. M.; Tallman, M. S. |
| Article Title: | Acute promyelocytic leukemia: What is the new standard of care? |
| Abstract: | Acute promyelocytic leukemia (APL) is one of the most exciting stories of modern medicine. Once a disease that was highly lethal, the majority of patients are now cured with the advent of molecularly targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). In many patients, chemotherapy can be omitted completely, particularly in patients with low- or intermediate-risk disease (white blood cell count. ≤. 10,000/μl). Recent data show overall survival exceeding 90% with ATRA and ATO-based induction and consolidation strategies. In the uncommon patient in whom relapse does occur, most can still be cured with ATO and autologous hematopoietic cell transplantation. Remaining challenges in APL management include the rapid identification and treatment of newly diagnosed patients to decrease the early death rate, optimizing treatment strategies in high-risk patients (white blood cell count. >. 10,000/μl), and the role of maintenance therapy in lower risk patients. © 2014 Elsevier Ltd. |
| Keywords: | event free survival; survival rate; overall survival; fatigue; review; cancer combination chemotherapy; monotherapy; disease free survival; cytarabine; methotrexate; anorexia; multiple cycle treatment; bone marrow suppression; nausea; qt prolongation; high risk patient; cancer resistance; arsenic trioxide; minimal residual disease; daunorubicin; promyelocytic leukemia; leukocyte count; idarubicin; heart arrhythmia; anthracycline derivative; leukemia relapse; blood clotting disorder; drug treatment failure; leukocytosis; retinoic acid; autologous hematopoietic stem cell transplantation; induction chemotherapy; gemtuzumab ozogamicin; mercaptopurine; acute promyelocytic leukemia; cheilitis; all-trans retinoic acid (atra); failure free survival; coagulopathy; maintenance chemotherapy; early death; human; priority journal; arsenic trioxide (ato); differentiation syndrome |
| Journal Title: | Blood Reviews |
| Volume: | 28 |
| Issue: | 5 |
| ISSN: | 0268-960X |
| Publisher: | Churchill Livingstone |
| Date Published: | 2014-09-01 |
| Start Page: | 205 |
| End Page: | 212 |
| Language: | English |
| DOI: | 10.1016/j.blre.2014.07.001 |
| PROVIDER: | scopus |
| PUBMED: | 25107311 |
| DOI/URL: | |
| Notes: | Export Date: 1 October 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work